The Honest Dose #16

I spent this week listening to a peptide-focused podcast, and one of the guests changed how I think about the people in this space.

If you have spent any time here, you know the pattern I am about to describe. A lot of the loudest voices behind these compounds are clinicians and coaches with real credentials, and those same voices are, not by coincidence, selling the exact compounds they are enthusiastic about. I do not think that makes them liars. Someone can believe in a therapy and also profit from it, and the belief can even be sincere. But it puts a permanent thumb on the scale. When the person telling you a peptide is safe and life-changing also makes money every time you decide they are right, the full-throated confidence stops being information. It is understandable, and it is still frustrating, and after a while it makes you crave a single honest voice that has nothing to sell you the moment it stops talking.

This guest was that voice, and it caught me off guard because she is not a skeptic. She is a clinician who prescribes these compounds, uses some of them herself, and has watched them change patients' lives. She holds a doctorate and this is her actual practice, not a side hustle. And she spent a meaningful part of the conversation talking about the downsides. Not in the throat-clearing way people do before they get to the sales pitch, but plainly: that even for the compounds she believes in most, the large-scale human safety data simply does not exist, and its absence is not a technicality. It means real adverse reactions can happen that nobody saw coming, because the studies that would have caught them were never run, and the data that would let anyone warn you is not sitting in a database waiting to be checked.

She gave one example that has stuck with me; she described a case ofma woman with diabetic retinopathy who lost her vision after using BPC-157. The mechanism she pointed to is real, and it is worth understanding. BPC-157 is thought to promote angiogenesis, the growth of new blood vessels, which is part of why it may help tissue heal. But diabetic retinopathy is itself a disease of abnormal blood-vessel growth in the eye. The standard treatments for it work precisely by blocking that growth. A compound that encourages new vessels is close to the last thing you would want acting on a retina already being damaged by too many of them. I want to be careful here, because one case cannot prove the peptide caused the outcome, and I am not going to pretend it can. But the point she was making never depended on proving causation. It was that this is exactly the kind of interaction that large-scale safety research is supposed to surface in advance, and for most of these compounds that research does not exist, so nobody is flagging it for you. You find out the hard way or you do not find out at all.

That is the whole reason this newsletter exists, and hearing it from someone who clearly loves what these compounds can do made it land harder than any critic ever could. You are allowed to be genuinely excited about the potential of these therapies for ordinary people, and honest about how thin the evidence underneath them still is. Those two things are not in tension. I think championing both at once is not fence-sitting. It is just the accurate position. And the lead this week is a compound that makes the point better than I could have scripted it, because it just did something no peptide in its class has ever done, and the thing it did means far less than the headline suggests.

Let's get into it.

This past September, SS-31 did something no compound like it had ever done. Under its generic name, Elamipretide, and the brand name FORZINITY, it received FDA accelerated approval, making it the first mitochondria-targeted therapeutic the agency has ever approved. For a class of compounds that has lived almost entirely in the research-chemical gray zone, that is a genuine milestone. It is also one of the cleanest illustrations I can give you of why "FDA approved" and "the evidence is strong" are not the same sentence.

What it is. SS-31 is a small mitochondria-targeting tetrapeptide, one of the Szeto-Schiller family of peptides. Its defining trick is not a receptor, it is a destination. It selectively concentrates in the inner mitochondrial membrane and binds cardiolipin, a phospholipid found almost nowhere else in the cell and essential to the structure of the electron transport chain, where the vast majority of your cellular energy is produced. By stabilizing cardiolipin, SS-31 is thought to improve the efficiency of that machinery, reduce the leak of reactive oxygen species, and blunt the signals that push a stressed cell toward death. The foundational biology here is genuinely strong, and it is why the compound has been chased for everything from heart failure to macular degeneration to ordinary aging.

What actually got approved, and it is narrower than it sounds. The approval covers one thing: improving muscle strength in Barth syndrome patients who weigh at least 30 kilograms. Barth syndrome is an ultra-rare, inherited, X-linked mitochondrial disease that affects roughly 150 people in the entire United States, almost all of them young boys, caused by a mutation that leaves them short on functional cardiolipin. So the single most important fact about this approval is that it is for a disease almost nobody reading this has, in a population almost nobody reading this belongs to. It says nothing about the reason most people in this space are actually interested in SS-31, which is anti-aging, "mitochondrial support," and general cellular energy. None of that was approved. None of that was even the question in front of the agency.

Now read the trial the approval rests on, because it matters. The approval was built on TAZPOWER, a randomized, double-blind, placebo-controlled crossover trial of twelve patients. Twelve. And in the randomized, placebo-controlled portion, the part designed to actually isolate whether the drug works, Elamipretide did not significantly beat placebo on its primary endpoints, which were a six-minute walk test and a fatigue score. The muscle-strength signal that the label is ultimately built on did not appear during the controlled comparison. It emerged later, during the open-label extension, when everyone involved knew they were receiving the drug. That is a meaningfully weaker form of evidence, and it is worth understanding that the FDA approved this compound not because a controlled trial cleanly demonstrated benefit, but through the accelerated pathway, which lets the agency approve a therapy for a devastating rare disease on more preliminary evidence and then require confirmatory trials to verify the benefit later. The approval can be revisited if those trials do not deliver.

This is the detail that most coverage will skip entirely. The very same molecule failed the primary endpoints of its Phase 3 trial in a different mitochondrial condition, primary mitochondrial myopathy. So SS-31's human record is not a story of a compound that works. It is a story of a compound with strong underlying biology, a rare-disease approval resting on a twelve-person trial and an open-label extension, and a separate Phase 3 failure in a related indication. That is a genuinely mixed record, and "the first FDA-approved mitochondrial peptide" flattens all of it into a marketing phrase.

Why it scores where it does. SS-31 sits at 50 on the Research Quality Score, in the Limited band. Some people will find that surprising for a compound that just earned an FDA approval, and the surprise is exactly the lesson. The RQS does not score regulatory status, and it does not score how exciting the mechanism is. It scores the methodological strength of the human research behind the claims people are actually making. For the narrow, approved use, the evidence is real but thin and rests heavily on a tiny trial. For the broad longevity use that drives most of the interest, the human translation is mixed to absent. A 50 is the honest number for a compound whose foundational science is impressive and whose human story is unfinished and uneven. The approval is a real event. It is not a verdict on the reasons most people are buying this.

One thing I want to be direct about. An accelerated approval for an ultra-rare disease is a good thing for the families it serves, and I am not minimizing it. What I am doing is refusing to let it be borrowed. The gap between "approved to improve muscle strength in Barth syndrome" and "FDA-approved mitochondrial peptide for anti-aging" is the entire distance this newsletter exists to keep visible. Watch how fast the marketing tries to close it.

RQS: 50/100 - Limited Evidence

Read the full SS-31 profile

The claim: There are actually two claims bundled together here, pointing in opposite directions, and they are both having a moment. The old one is a fear: that testosterone is a male hormone, and a woman who takes it, or even who lifts heavy weights, risks becoming bulky, deep-voiced, and masculine. The new one is a promise, rising fast in the menopause and wellness conversation: that testosterone is the missing piece, the hormone that fixes the fatigue, the brain fog, the low mood, and the low libido of midlife, and that hormone therapy is not just for men. You will find loud, confident voices on both sides, and the honest answer runs straight down the middle of them.

The reality: Start with what is true, because a surprising amount of it is.

Women make testosterone. The ovaries and adrenal glands produce it throughout life, and levels decline with age. So the framing of testosterone as a purely male hormone is simply wrong on the biology. And the masculinization fear, at the doses that matter, is largely overblown. Virilization, the deepening voice and the rest, is a feature of supraphysiologic exposure, meaning levels pushed well above what a woman's body would ever produce on its own. At genuine physiologic replacement, aiming to restore the levels of a healthy younger woman rather than exceed them, those effects are not expected. The catch is that some of the delivery methods driving the current boom, injectables, pellets, and compounded preparations, are exactly the ones most prone to overshooting into that supraphysiologic range, which is where both the masculinizing risk and the evidence gap actually live. So the fear is real only in the corner of the practice where dosing goes off the rails.

Now the promise, and this is where the enthusiasm outruns the evidence. There is a large, credentialed international consensus on testosterone therapy for women, endorsed by more than ten major medical societies. Its central finding is narrow and specific: the one evidence-based use of testosterone in women is for hypoactive sexual desire disorder, distressing low libido, primarily in postmenopausal women. For that, the randomized trial evidence is real. For everything else, the same consensus is blunt: there is insufficient evidence to recommend testosterone for energy, mood, cognition, bone, muscle, or general wellbeing in women. Not "it definitely does nothing." Just that the studies do not support the confident claims, and the panel specifically advised against compounded testosterone because the dosing is unreliable.

And here is the correction I want to make carefully, because it is easy to get backwards. The worst symptoms of perimenopause and menopause, the hot flashes, the night sweats, the sleep disruption, are driven mainly by the decline in estrogen, not testosterone. Testosterone is not the hormone doing that damage, and replacing it is not the fix for those symptoms. When the current messaging attaches the entire misery of menopause to low testosterone, it is borrowing the genuine, under-treated reality of menopause, which is largely an estrogen story, and pinning it on the hormone with the most marketable "vitality" halo. That is the overreach.

You will notice the shape of this is familiar. There is a true, under-appreciated core, women make testosterone, it declines, the masculinization panic is mostly unfounded, and hormone therapy is emphatically not just for men. Wrapped around that core is a promise the evidence does not carry, that testosterone is the master fix for midlife. The honest move is to hold the core and drop the wrapper.

The honest version of the claim: Testosterone is not a male-only hormone, and the fear that physiologic replacement will masculinize a woman is largely unfounded, that is a supraphysiologic-dose problem, not a replacement-dose one. The one use with solid evidence behind it is low sexual desire in postmenopausal women. But testosterone is not the cure-all for menopause it is increasingly sold as, the signature symptoms of menopause are mostly an estrogen story, and the broader promises of energy, mood, and cognitive rescue rest on evidence the field's own consensus calls insufficient. Hormone therapy for women is real, overdue, and worth taking seriously. That is exactly why it deserves better than one hormone oversold as the answer to everything.

This section discusses hormones and menopause in a general, informational way. Decisions about hormone therapy are genuinely individual and belong with a clinician who can look at your labs, your history, and your risks, not a newsletter.

I want to put two mitochondrial peptides side by side this week, because they land in the same RQS band for opposite reasons, and understanding why is the fastest way to understand what the score is actually measuring.

SS-31 scores 50. MOTS-c scores 41. Both sit in the Limited band, 40 to 59. If you only saw the band, you might assume these two compounds are in roughly the same evidentiary position. They are not even close, and the interesting part is that the score still puts them near each other honestly.

SS-31 earned its 50 the hard way, by actually being put through human trials that returned a mixed answer. It has real Phase 3 clinical data. It has an FDA approval. Those things earn genuine points on the dimensions the RQS weighs most, particularly study design. But it loses points elsewhere in ways worth naming, because the strongest trial is tiny, the human results are inconsistent across indications, and the pivotal myopathy trial was conducted in a population that was about 94 percent white, which scores a 1 out of 5 on population diversity and honestly limits how far those findings generalize. So SS-31's 50 describes a compound with real human evidence that is thin, uneven, and narrow. It reached the Limited band by doing the research and getting a complicated result.

MOTS-c sits at 41 from the other direction entirely. It is a fascinating molecule, a 16-amino-acid peptide encoded inside your own mitochondrial DNA, discovered in 2015, that activates the same AMPK energy pathway your body triggers during exercise, which is why it gets called an "exercise mimetic." The mechanism is elegant and the animal data is genuinely interesting. And there are no completed human clinical trials at all. Its score is not low because the biology is weak. It is low because the human research that would let you trust the biology has not been done. MOTS-c reached the Limited band not by getting a mixed result in people, but by never being tested in people.

That is the entire point of the RQS in one comparison. It does not reward excitement, mechanism, or a compelling origin story, and it does not treat an FDA approval as a trump card. One of these compounds was tested in humans and came back complicated. The other has not been tested in humans yet. The RQS makes that difference legible even though both round to "Limited," and it refuses to let a strong mechanism or a regulatory headline stand in for the human evidence that neither compound fully has. As always, the number measures research quality and nothing else. It is not a safety rating, it is not an efficacy rating, and it is not me telling you whether either one works.

Watch "FDA-approved mitochondrial peptide" become gray-market marketing copy. The FORZINITY approval in the lead is the first time any mitochondria-targeted peptide has earned FDA approval, and the most predictable thing in this entire space is what happens next. The approval covers muscle strength in an ultra-rare pediatric disease. The gray market sells SS-31 as an anti-aging and cellular-energy compound. Those are different universes, and I would bet on the phrase "FDA-approved" migrating from the first to the second within the month, stripped of every qualifier that makes it accurate. If you see SS-31 marketed for longevity with an FDA badge attached, you are watching a narrow rare-disease approval get laundered into a general endorsement it was never given. The approval is real. The way it will be used in copy is the thing to distrust.

The legal middle lane for GLP-1s is being closed for good. The FDA is advancing a proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulk substances list. In plain terms, if it is finalized, large-scale compounding pharmacies would be barred from making these from bulk ingredients under any circumstances, even if a future shortage returns. This is the same drug-versus-access story I keep coming back to: the shortages that once made legal, licensed compounding possible have resolved, and the regulatory door that opened during them is now being nailed shut on purpose. It is a slower, quieter version of the retatrutide fight I covered last issue, and it points the same direction. The legitimate middle path between the brand-name product and the black market keeps narrowing.

When compounders "differentiate," they invent molecules nobody has studied. Here is a concrete downstream effect of that squeeze. To keep selling compounded GLP-1s without running afoul of the rule against copying a commercially available drug, some compounders add extra ingredients, most commonly vitamin B12, but also B6, niacinamide, glycine, or carnitine, none of which have proven weight-loss benefit. That would be merely pointless if it were inert. It is not always inert. A 2026 analysis found that when tirzepatide is compounded with B12, the two can chemically bond into a new molecule that does not exist in the FDA-approved drug, a finding the manufacturer reproduced in its own testing. Nobody knows what that new molecule does, because it has never been studied in anyone. It is a perfect miniature of this whole newsletter's thesis: a regulatory workaround, dressed up as an upgrade, quietly creating an unknown that the marketing will never mention.

To close the loop on this issue's mitochondrial thread, I want to introduce the other end of the spectrum. If SS-31 is the mitochondrial peptide with an FDA approval and a mixed human record, Humanin is the mitochondrial peptide with one of the most extraordinary origin stories in the entire catalog and almost no human data at all.

Humanin belongs to the same strange family as MOTS-c, the mitochondrial-derived peptides, molecules encoded not in the nucleus but inside your mitochondrial DNA itself. The little organelles powering your cells carry their own genes for signaling peptides that talk back to the rest of the body. Humanin was discovered in 2001, researchers identified it in the surviving brain tissue of a patient who had died with Alzheimer's disease, in a region that had somehow been spared. They named it Humanin. It appears to protect cells from programmed death, shows neuroprotective activity in the lab, and circulates at levels that decline as we age, which is why it draws interest for Alzheimer's, cardiovascular protection, and longevity.

And it scores 37, in the Weak band. No completed human clinical trials. The evidence is animal and in vitro, the origin story is genuinely moving, the mechanism reads like science fiction in the best way, and none of that changes the number, because none of that is human outcome data. That is not the RQS being harsh. It’s the RQS being consistent. Put the three compounds from this issue in a row and you can see the whole instrument working: SS-31 at 50, with an approval and a thin, mixed human record; MOTS-c at 41, all mechanism and mouse data, untested in people; Humanin at 37, a beautiful idea with real biology and essentially no human trials behind it. Three mitochondrial peptides, three different distances from the evidence that would let you actually trust them, and one score that tells you honestly where each one stands. The excitement is allowed. The score is what keeps it honest.

RQS: 37/100 - Weak Evidence

Read the full Humanin profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.